China's Azvudine(阿兹夫定片):Pictures,Uses,Dosage,Side Effects,Warnings-SEAGULL HEALTH

Introduction of Azvudine

Azvudine can clear viruses while activating the immune system to address both the symptoms and root causes. It achieves potent viral suppression at low doses, with low risk of drug resistance, predominantly mild adverse reactions, and favorable medication safety profile.

Indications

Azvudine, in combination with nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs), is indicated for the treatment of adult patients infected with HIV-1 who have a high viral load (HIV-1 RNA ≥ 100000copies/ml).

Overview

Generic Name

Azvudine Tablets,阿兹夫定片

Brand Name

捷倍安

Drug Type

Rx Drug

Approval No.

1mg:国药准字H20210035;3mg:国药准字H20210036

Active Ingredient

Azvudine

Dosage Form

1mg*35tablets;3mg*35tablets

Specification

Tablets

Description

This product is a white or off-white tablet.

Expiry Date

12 months

Manufacturer

Genuine Biotech Co., Ltd.

Storage

Store in a tightly sealed container at a temperature not exceeding 30℃.

Dosage and Administration

Initial treatment of HIV-1-infected patients should be conducted by physicians experienced in the treatment of HIV infection.

To ensure the correct dosage, the tablets should be swallowed whole and must not be crushed. The recommended dosage for adult patients is 3mg per dose, once daily, to be taken orally on an empty stomach before bedtime.

Contraindications

Contraindicated in patients hypersensitive to Azvudine or any other components of the formulation.

Adverse Reactions

Study results indicate that single doses of 1mg to 5mg of Azvudine Tablets are safe and tolerable in HIV-infected patients. All adverse reactions reported are mild, mainly manifesting as fever, dizziness, nausea, diarrhea, etc. These reactions have all been documented with similar marketed anti-HIV drugs, and all symptoms resolve spontaneously or with symptomatic treatment.

During the 48-week administration period, all adverse reactions observed are common with marketed anti-HIV drugs, mainly including dizziness, elevated alanine aminotransferase (ALT), elevated γ-glutamyl transferase (GGT), and elevated aspartate aminotransferase (AST), with the severity mostly being Grade 1-2.

Use in Special Populations

Use in Pregnant and Lactating Women

Studies on the use of this product in pregnant and lactating women have not been conducted.

Pediatric Use

Pediatric studies of this product have not been conducted.

Geriatric Use

Studies of this product in geriatric patients have not been conducted.

For more detailed drug information, please consult the official package leaflet.

Contact Information

If any issues arise, please contact us immediately.

Email:haiousales@gmail.com